Expert Interview
A Second Opinion: Discussing the FDA approval of Daiichi Sankyo's new first-line AML drug, quizartinib with boxed warning for heart disorders
Ticker(s): DSKYFInstitution: Presbyterian Medical Group
- Hematologist at Presbyterian Medical Group in Albuquerque, NM (community practice affiliated with a teaching hospital).
- Completed his internal medicine residency at the University of Indiana in Indianapolis and an additional three years of fellowship training in hematology and oncology at Baylor College of Medicine and MD Anderson.
- treats 49 patients with unresectable hepatocellular carcinoma and is familiar with the HIMALAYA Phase III trial and the STRIDE regimen
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
